Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Zykadia
(United States) [Available]Synonyms :
ceritinib (Rx) 
Class :
Antineoplastics and Anaplastic Lymphoma Kinase Inhibitor 
Brand Name :
Zykadia
(United States) [Available]Synonyms :
ceritinib (Rx) 
Class :
Antineoplastics and Anaplastic Lymphoma Kinase Inhibitor 
450
mg
Capsule
Oral
once a day
Continue the therapy until disease progression or unacceptable toxicity occurs 
Dose Adjustments
Renal impairment:  Mild/moderate renal impairment (CrCl 30 < 90 ml/min):   No adjustment recommended.  Severe renal impairment (CrCl <30 ml/min):   Data not available  Liver impairment:  Mild (Child-Pugh A/B):   No adjustment recommended.  Severe (Child-Pugh C):   Reduce dose to one third and round to the nearest multiple of the 150 mg dose strength
Safety and efficacy not established  
Refer adult dosing
when both drugs are combined, there may be increase in the serum concentration of abemaciclib 
when both drugs are combined, there may be increase in the bradycardic effect of ceritinib  cerit
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
may increase the bradycardic effect of bradycardia-causing agents
may increase the bradycardic effect of bradycardia-causing agents
may increase the bradycardic effect of bradycardia-causing agents
may increase the bradycardic effect of bradycardia-causing agents
may increase the bradycardic effect of bradycardia-causing agents
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with ceritinib
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ceritinib: they may increase the bradycardic effect of Bradycardia-Causing Agents
ceritinib: they may increase the bradycardic effect of Bradykinin receptor antagonists
when both drugs are combined, there may be an increase in qtc interval  
it may increase the bradycardic effect of ceritinib 
may increase the bradycardic effect
may increase the bradycardic effect of bradycardic agents
may increase the bradycardic effect of bradycardia causing agents
moexipril/hydrochlorothiazideÂ
may increase the bradycardic effect of bradycardia causing agents
may enhance the bradycardic effect of bradycardia causing agents
may increase the bradycardic effect of bradycardia causing agents
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the bradycardic effect of Bradycardia-Causing Agents
when both drugs are combined, there may be increase in the serum concentration of acalabrutin 
when both drugs are combined, there may be increase in ceritinib and arsenic trioxide both increase QTc interval
when both drugs are combined, there may be increase in both increase QTc interval 
when both drugs are combined, there may be increase in both increase QTc interval 
when both drugs are combined, there may be increase in both increase QTc interval 
when both drugs are combined, there may be increase in both increase QTc interval  arsenic trioxide 
when both drugs are combined, there may be increase in both increase QTc interval 
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
It may enhance the effect when combined with irinotecan liposomal by affecting CYP3A4 metabolism
It may enhance QTc interval when combined with lithium
nafcillin will decrease the effect of action of ceritinib by affecting enzyme CYP3A4 metabolism.
when both drugs are combined, both increase the QTC interval  
when both drugs are combined, both increase the QTC interval   
both lapatinib and ceritinib increase the QTc interval
when used together, azithromycin and ceritinib both increase the QTc interval
midostaurin and ceritinib, when used simultaneously, increase the QTc level
when both drugs are combined, there may be an increase in the QTC interval
midostaurin and ceritinib, when used simultaneously, increase the QTc level
It may enhance QTc interval when combined with pentamidine
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
when ajmaline is used together with ceritinib, the risk or seriousness of QTc prolongation is enhanced
When alprazolam and ceritinib is used together, this leads to reduction in the alprazolam’s metabolism
ceritinib: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
ceritinib: they may increase the CNS depressant effect of CNS Depressants
When ponesimod is used together with ceritinib, this leads to enhanced risk or seriousness of bradycardia
When ceritinib is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When ceritinib is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
ceritinib: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
ceritinib: they may increase the anticoagulant effect of anticoagulants
When ceritinib is used together with oleandomycin, this leads to enhanced concentration serum of ceritinib
When ceritinib is used together with patupilone, this leads to enhanced concentration serum of ceritinib
When ceritinib is used together with ridaforolimus, this leads to enhanced concentration serum of ceritinib
piperine, when combined with ceritinib, may lead to an increased serum concentration of ceritinib
ceritinib: it may decrease the therapeutic efficacy of dextropropoxyphene
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with ceritinib, this leads to elevated hyperglycemia risk
when both drugs are combined, there may be a decreased metabolism of etoposide   
when both drugs are combined, there may be an increased metabolism of ceritinib  
when both drugs are combined, there may be a reduced excretion rate of topotecan and result in an elevated level of serum concentration  
QTc interval is increased both by lenvatinib and ceritinib
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
fedratinib increases the effect of ceritinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
when both drugs are combined may enhance the bradycardia effect and raise blood pressure
Ceritinib inhibits the enzyme Anaplastic lymphoma kinase (ALK), commonly referred to as the ALK tyrosine kinase receptor, which is expressed by the ALK gene in humans.Â
Chromosome rearrangement in approximately 4–5% of NSCLCs results in a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase). This constitutive kinase activity contributes to carcinogenesis and appears to be the primary cause of the malignant phenotype.Â
Ceritinib inhibits the growth of EML4-ALK-positive NSCLC xenografts in mice and rats in a dose-dependent manner. It has also been reported to reduce the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins.Â
Adverse drug reactions: Â
Frequency defined Â
Adverse Effects Â
>10% (All grades) Â
Diarrhea (85%) Â
Increased gamma-glutamyl transpeptidase (GGT) (84%) Â
Increased alkaline phosphatase (81%) Â
Fatigue (45%) Â
Abdominal pain (40%) Â
Non-cardiac chest pain (21%) Â
Increased total bilirubin (15%) Â
Dizziness (12%) Â
Prolonged QT interval (12%) Â
Musculoskeletal pain (11%) Â
Rash (21%) Â
Back pain (19%) Â
Pyrexia (19%) Â
Headache (19%) Â
Increased amylase (37%) Â
Decreased phosphate (38%) Â
Decreased appetite (34%) Â
Neutropenia (27%) Â
Cough (25%) Â
Increased creatinine (77%) Â
Nausea (69%) Â
Vomiting (67%) Â
Anemia (67%) Â
Hyperglycemia (53%) Â
Weight loss (24%) Â
Constipation (20%) Â
Thrombocytopenia (16%) Â
Esophageal disorder (15%) Â
Pruritus (11%) Â
>10% (Grades 3-4) Â
Increased aspartate transaminase (AST) (21%) Â
Increased alkaline phosphatase (12%) Â
Increased gamma-glutamyl transpeptidase (GGT) (49%) Â
Increased alanine transaminase (ALT) (34%) Â
1-10% (Grade 3-4) Â
Anemia (4.2%) Â
Abdominal pain (3.7%) Â
Increased lipase (6%) Â
Vomiting (5%) Â
Diarrhea (4.8%) Â
Increased creatinine (4.2%) Â
Hyperglycemia (10%) Â
Increased amylase (8%) Â
Fatigue (7%) Â
Â
None
Contraindication:Â
None Â
Caution:Â
Drug-induced hepatotoxicityÂ
HyperglycemiaÂ
BradycardiaÂ
Gastrointestinal adverse reactionsÂ
Pregnancy warnings:    Â
Breastfeeding warnings: Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester.      Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.      Â
Category N: There is no data available for the drug under this category
Ceritinib inhibits the growth of ALK-dependent cancer cells, ALK-mediated phosphorylation of the downstream signalling molecule STAT3, and autophosphorylation of ALK.Â
Anaplastic lymphoma kinase (ALK), insulin receptor (InsR), insulinlike growth factor 1 receptor (IGF-1R), and ROS1 are all targets of this tyrosine kinase inhibitor.Â
It is taken orally in tablet form with food.Â
If patient missed a dose, then they should make it up unless the following dose is due in 12 hours.Â
During vomited dose, proceed with the next planned dose if vomiting happens during therapy.Â
Patient information leafletÂ
Generic Name: ceritinibÂ
Why do we use ceritinib?Â
Patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive are treated with the kinase inhibitor ceretinib.Â
The tumor response rate and response duration determine the accelerated approval status of this indication.Â
Verification and description of clinical benefit in confirmatory trials may be necessary for this indication’s continued approval.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
